1. Home
  2. QDEL

as of 11-13-2026 3:38pm EST

$10.73
+$0.15
+1.42%
Stocks Health Care Medical Specialities Nasdaq

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

Founded: 1979 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 989.5M IPO Year: 2022
Target Price: $15.00 AVG Volume (30 days): 2.2M
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.49 EPS Growth: 45.35
52 Week Low/High: $9.92 - $35.58 Next Earning Date: 11-03-2026
Revenue: $2,730,200,000 Revenue Growth: -1.89%
Revenue Growth (this year): -7.71% Revenue Growth (next year): -0.18%
P/E Ratio: -3.03 Index:
Free Cash Flow: -83000000.0 FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 3, 2026 · 100% conf.

AI Prediction BUY

1D

+8.94%

$15.35

Act: +1.85%

5D

+6.40%

$14.99

20D

+3.09%

$14.53

Price: $14.09 Prob +5D: 100% AUC: 1.000
0001906324-26-000040

EX-99.1

2 qdel9272026ex991earningsre.htm

EX-99.1

Document

Exhibit 99.1

QuidelOrtho Reports Third Quarter 2026 Financial Results

― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ―

― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ―

― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ―

November 3, 2026

SAN DIEGO, CA November 3, 2026 — QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a leading global provider of diagnostic solutions, today announced financial results for the third quarter ended September 27, 2026.

Key Third Quarter 2026 Results:

(all comparisons are to the prior year period)

•Total revenue was $619 million, a decrease of 12% both as reported and in constant currency. Excluding respiratory, China, and the U.S. Donor Screening business, total revenue grew 2% as reported and 3% in constant currency, reflecting the underlying strength of the business.

◦Labs revenue of $353 million declined 6% both as reported and in constant currency, primarily due to lower sales in China related to recently announced changes to In Vitro Diagnostics pricing. Outside China, Labs revenue grew 3% as reported and 4% in constant currency, driven by continued strength across the business.

◦Immunohematology revenue of $142 million was flat as reported and increased 1% in constant currency. Outside China, Immunohematology revenue grew 2% as reported and 3% in constant currency.

◦Point of Care revenue of $120 million declined 27% both as reported and in constant currency due to a softer respiratory season.

•GAAP net loss was $54 million; GAAP operating loss was $8 million; adjusted EBITDA was $148 million.

•GAAP net loss margin was 8.7%; GAAP operating loss margin was 1.2%; adjusted EBITDA margin was 23.9%.

•GAAP diluted loss per share was $0.78; adjusted diluted earnings per share (“EPS”) was $0.31.

•Operating cash flow was $20 million; free cash flow was $0.3 million.

“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base,” said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. “While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program. This program is designed to improve profitability and cash flow while evolving our operating model around the distinct needs of our customers and markets. We believe these actions will help mitigate near-term headwinds and position the Company for sustainable long-term growth.”

Cost Transformation and Restructuring Program

The Company has initiated a new cost transformation and enterprise restructuring program designed to further improve its cost structure and evolve its operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics. The new operating model is designed to increase customer focus, create clearer accountability for business performance, and better align technology development and investment priorities with the distinct needs of each business. The Company expects the program to deliver over $80 million in annual savings in 2027 and to record approximately $30 to $35 million in one-time restructuring charges in the fourth quarter of 2026.

Full-year 2026 Financial Guidance

Based on its current business outlook, the Company is updating its full-year financial guidance below:

Full-year 2026 Financial GuidanceAs of 11/3/2026As of 8/6/2026

Total revenues (reported)$2.52 - $2.54 billion$2.52 - $2.60 billion

Adjusted EBITDA$540 - $545 million$540 - $560 million

Adjusted EBITDA margin ~21%21% - 22%

Adjusted diluted EPS$0.65 - $0.70$0.65 - $0.90

Please see page 8 of the Third Quarter 2026 Financial Results presentation on the “Investor Relations” page of the Company’s website for the full list of assumptions on which the Company’s current 2026 financial guidance is based.

A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non-recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty th

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 6, 2026 · 99% conf.

AI Prediction BUY

1D

+8.91%

$17.77

Act: -24.72%

5D

+6.38%

$17.36

20D

+3.08%

$16.82

Price: $16.32 Prob +5D: 100% AUC: 1.000
0001906324-26-000032

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1786061740.e0aafc34

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K SELL

May 5, 2026 · 100% conf.

AI Prediction SELL

1D

-9.55%

$10.55

Act: -6.00%

5D

-10.63%

$10.42

Act: -4.63%

20D

-10.12%

$10.48

Act: +16.64%

Price: $11.66 Prob +5D: 0% AUC: 1.000
0001906324-26-000023

EX-99.1

2 qdel3292026ex991earningsre.htm

EX-99.1

Document

Exhibit 99.1

QuidelOrtho Reports First Quarter 2026 Financial Results

― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ―

― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ―

― Company Updates Full-Year 2026 Financial Guidance ―

May 5, 2026

SAN DIEGO, CA May 5, 2026 — QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026.

Key First Quarter 2026 Results:

(all comparisons are to the prior year period)

•Total revenue was $620 million, as reported

◦Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.

◦Labs revenue of $353 million declined by 5% as reported and 8% in constant currency, primarily due to slower distributor sales in China that the Company believes is related to pending changes to the China National Health Security Administration (“NHSA”) In Vitro Diagnostics (“IVD”) pricing guidelines, business disruption related to the Middle East conflict, and a decrease in revenue related in part to the Company’s termination of its joint business arrangement with Grifols.

◦Immunohematology revenue of $138 million grew 8% as reported and 3% in constant currency, primarily driven by growth in North America, China and JPAC.

•GAAP net loss was $92 million; GAAP operating loss was $32 million; adjusted EBITDA was $109 million.

•GAAP diluted loss per share was $1.35; adjusted diluted loss per share was $0.04.

“Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business disruption in China and the Middle East,” said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. “Importantly, we believe the underlying business remains strong and we are well positioned to deliver on our objectives to expand our adjusted EBITDA margin and improve cash flow in 2026.”

“We completed our acquisition of LEX Diagnostics in April, adding an ultra-fast molecular diagnostics platform for point-of-care testing. We also advanced our key strategic priorities, including the U.S. launch of our High-Sensitivity Troponin assay and the rollout of the VITROS 450 platform in select international markets. We believe these innovations enhance our portfolio and position us to drive sustainable, long-term growth,” Blaser continued.

Full-year 2026 Financial Guidance

The Company provided its initial financial guidance for full-year 2026 on February 11, 2026. On April 15, 2026, the Company announced preliminary revenue for the first quarter 2026 and indicated that the low end of its full-year 2026 financial guidance ranges remained achievable. Considering first-quarter performance and current market dynamics in China, the Company has updated its previously provided financial guidance. This guidance includes expected 2026 impact from the current draft of the China NHSA IVD pricing guidelines. The Company cannot fully assess the impact until the final NHSA guidelines and implementation timelines are confirmed. In addition, this guidance does not assume a significant, prolonged impact related to the Middle East conflict.

Full-year 2026 Financial GuidanceUpdated (as of 5/5/26)Previous (as of 2/11/26)

Total revenues (reported)$2.70 - $2.75 billion$2.7 - $2.9 billion

Adjusted EBITDA$615 - $630 million$630 - $670 million

Adjusted EBITDA margin 23%23.3%

Adjusted diluted earnings per share$1.80 - $2.00$2.00 - $2.42

Free cash flow$100 - $120 million$120 - $160 million

Please see page 6 of the First Quarter 2026 Financial Results presentation on the “Investor Relations” page of the Company’s website for the full list of assumptions on which the Company’s current 2026 financial guidance is based.

A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted diluted earnings per share and free cash flow, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non-recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors. See "Forward-Looking Statements" and "Non-GAAP Financial Measures."

Conferen

Share on Social Networks: